Pia Klöpfer

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma

Karim Chamie, Nicholas M. Donin, Pia Klöpfer et al. · JAMA Oncology · 2016 · 134 citations · Full text

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial

Karim Chamie, Pia Klöpfer, Paul Bevan et al. · Urologic Oncology Seminars and Original Investigations · 2015 · 41 citations

Carbonic Anhydrase-ix Score, Prognostic Biomarkers, Urology +8

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma

Nicholas M. Donin, Allan J. Pantuck, Pia Klöpfer et al. · Cancer Epidemiology Biomarkers & Prevention · 2016 · 27 citations

First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.

David Belada, Kateřina Kopečková, Juan Bergua et al. · Journal of Clinical Oncology · 2021 · 12 citations

Cell Therapy, Immunodeficiencies, Immunology +23

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt et al. · Blood · 2015 · 12 citations